Imugene’s $20 million boost and cancer trial updates
Published: 10:05 03 Feb 2025 AEDT
Imugene Ltd chief operating officer Brad Glover and managing director and CEO Leslie Chong talked with Proactive’s Tylah Tully about the company’s latest Appendix 4C quarterly report, which provided several key updates for shareholders and investors.
The pair also discussed the recent $20 million received from CVI Investments, ongoing clinical trials and financial outlook for 2025.
Chong provided updates on Imugene’s metastatic advanced solid tumour study (MAST), highlighting that a cholangiocarcinoma patient has been in full remission for over two years.
She also shared news on the company securing a patent for its CF33 oncolytic virus technology, which extends until 2040.
Glover discussed progress in Imugene’s oncolytic virus program, stating that the company has initiated a combination trial with a CD19-targeting bispecific antibody.
He also detailed the expansion of the Azer-cel trial, noting that the first Australian site has opened, and initial results from US sites have been promising.
Financially, Chong reported that Imugene has approximately $65.4 million in cash, ensuring funding through 2025.
Looking ahead, Glover emphasised the company’s focus on clinical execution and data generation in 2025.
